Biopsy of breast cancer metastases: patient characteristics and survival
Shlomit Strulov Shachar(Tel Aviv Sourasky Medical Center), Gil Bar‐Sela(Emek Medical Center), Hyman B. Muss(University of North Carolina at Chapel Hill), Georgeta Fried(Roche (Switzerland)), Noa Shafran(Technion – Israel Institute of Technology), Karen Drumea(Rambam Health Care Campus), Tanya Mashiach(Rambam Health Care Campus)
Cited by 18
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
|Current Medicinal Chemistry|2009|480
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
|Nature Medicine|2019|328